Clinical Report: Incorporation of a National Rare Disease Registry into a Data Warehouse

Overview

This report discusses the integration of the French Rare Eye Disease Database (FREDD) into the existing national rare disease data infrastructure, highlighting the importance of seamless data interoperability. The initiative aims to enhance research capabilities and improve patient care for rare eye conditions.

Background

Rare diseases, by their nature, affect small populations, complicating data collection and research efforts. In France, the establishment of a structured network for rare diseases has been a public health priority since 2005, leading to the creation of various data repositories. The integration of FREDD into the existing data ecosystem addresses the critical need for efficient data collection and utilization in rare eye disease research.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• The FREDD database was developed to support the secondary use of clinical data from patients with rare eye diseases.
• FREDD aims to facilitate translational research and cohort building across multiple clinical centers.
• Direct data retrieval from BaMaRa minimizes inconsistencies and reduces the burden on healthcare professionals.
• FREDD's data will support projects leveraging artificial intelligence for improved diagnosis and treatment of rare eye diseases.
• Interoperability initiatives, such as REDgistry and the JARDIN project, aim to enhance data sharing and standardization across Europe.

Clinical Implications

The integration of FREDD into the national data infrastructure enhances the ability to conduct research on rare eye diseases, potentially leading to improved patient outcomes. Clinicians can benefit from streamlined data collection processes, allowing them to focus more on patient care rather than administrative tasks.

Conclusion

The establishment of FREDD represents a significant advancement in the management and research of rare eye diseases in France. By improving data interoperability, this initiative has the potential to enhance both clinical practice and research outcomes.

Related Resources & Content

1. Drug Safety, 2021 -- Gathering Information from Rare Disease Registries to Aid Regulatory Decisions
2. npj Digital Medicine, 2026 -- A semi-supervised transformer model for diagnosing rare diseases
3. Drug Safety, 2019 -- Utilization of Patient Registries: A Valuable Yet Underexploited Tool for Drug Assessment
4. Regulation - EU - 2025/327 - EN - EUR-Lex
5. European Rare Disease Registry Infrastructure (ERDRI) | European Platform on Rare Disease Registration
6. npj Digital Medicine — Information content as a health system screening tool for rare diseases
7. First patients enrolled in REDgistry – July 2023 - ERN-EYE
8. Volet SDM-MR – Set de données minimum – Maladies rares | Agence du Numérique en Santé
9. Regulation - EU - 2025/327 - EN - EUR-Lex
10. European Rare Disease Registry Infrastructure (ERDRI) | European Platform on Rare Disease Registration
11. Guide d’implémentation du SDM Maladies Rares dans les DPI | Banque Nationale de Données Maladies Rares
12. Un cadre d'interopérabilité pour les maladies rares | Banque Nationale de Données Maladies Rares
13. The Orphanet Nomenclature of rare diseases: a standard terminology for improved patient recognition and data interoperability | medRxiv
14. An ontology-based rare disease common data model harmonising international registries, FHIR, and Phenopackets | Scientific Data
15. Guideline on registry-based studies | European Medicines Agency (EMA)
16. EMA adopts reflection paper on RWE from noninterventional studies | RAPS
17. THE FIGHT INHERITED RETINAL BLINDNESS! PROJECT: A New Treatment Outcome and Natural History Registry for Inherited Retinal Disease - PubMed
18. About the Data: IRIS® Registry | Vision and Eye Health Surveillance System | CDC